站内搜索
最新录用更多>>
双靶点药物NL-101的抗多发性骨髓瘤活性及其机制研究
    点此下载全文
引用本文:杨岚,葛求富,郭殿武,徐伟良,赵丽.双靶点药物NL-101的抗多发性骨髓瘤活性及其机制研究[J].中国药科大学学报(中文版),2017,48(4):469-475
摘要点击次数: 84
全文下载次数: 123
作者单位
杨岚 杭州民生药物研究院有限公司 
葛求富 杭州民生药物研究院有限公司 
郭殿武 杭州民生药物研究院有限公司 
徐伟良 杭州民生药物研究院有限公司 
赵丽 中国药科大学基础医学与临床药学学院 
中文摘要:研究具有组蛋白去乙酰化酶(histone deacetylase,HDAC)抑制和DNA损伤双靶点化合物NL-101的体内外抗多发性骨髓瘤活性及其机制研究。在10株多发性骨髓瘤细胞株中,采用CTG法检测化合物NL-101对肿瘤细胞增殖的影响以及在RPMI 8226细胞中NL-101与硼替佐米的联用效果,采用流式细胞仪检测NL-101对细胞周期的影响,Western blot检测NL-101对乙酰化组蛋白H3、乙酰化α-Tubulin和磷酸化Histone H2A.X的表达影响,并在RPMI 8226多发性骨髓瘤细胞皮下移植瘤模型中考察NL-101单用以及与硼替佐米联用的抑瘤效果。研究结果表明,NL-101能同时产生HDAC抑制剂和DNA烷化剂双重活性,不但抑制肿瘤细胞组蛋白去乙酰化水平,而且增加DNA损伤,最终诱导细胞周期阻滞和细胞凋亡。在细胞水平和动物移植瘤模型中均表现出较强的抗肿瘤活性,优于阳性对照药美法仑,而且与硼替佐米联用具有协同增效作用。NL-101有望成为一个全新的抗多发性骨髓瘤药物。
中文关键词:NL-101  DNA损伤  HDAC抑制剂  双靶点  抗肿瘤活性
 
Antitumor effects and the mechanisms of dual-targeting drug NL-101 on human multiple myeloma
Abstract:The antitumor activities of NL-101, aHDACi/DNA damage dual-targeting drug, on human multiple myeloma in vitro and in vivo were studied. Furthermore, the primary mechanisms were revealed. We detected the anti-proliferative activity of NL-101 on 10 human multiple myeloma cell lines, and the combinational effect of NL-101 and bortezomib on RPMI 8226 cell line. The inducing effects of NL-101 on cell cycle arrest and apoptosis were detected by FACS. The effects of NL-101 on acetyled-Histone H3, total Histone H3, acetyled α-Tubulin, total α-Tubulin, phospho-Histone H2A. X and total Histone H2A. X were evaluated by Western blott. We also demonstrated the antitumor activity of NL-101 and the combinational effect of NL-101 and bortezomib on RPMI 8226 xenograft tumor model in vivo. Results showed that NL-101 possessed strong antitumor activities on human multiple myeloma cells in vitro and in vivo. NL-101exhibited significant HDAC inhibitory activity and DNA alkylating activity. NL-101not only inhibited histone deacetylation level, but also increased the DNA damage in multiple myeloma cells. Meanwhile, NL-101 induced cell cycle arrest and apoptosis. Also, the synergistic effect of NL-101 was discovered when combined with bortezomib in vitro and in vivo. These data demonstrated that NL-101 may be a potent agent for the treatment of human multiple myeloma in future.
keywords:NL-101  DNA damage  HDAC inhibitor(HDACi)  dual-targeting  antitumor activity
查看全文  查看/发表评论  下载PDF阅读器
分享按钮